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OBJECTIVE—A selective rise in hypothalamic lipid metabolism
and the subsequent activation of SUR1/Kir6.2 ATP-sensitive K

(KATP) channels inhibit hepatic glucose production. The mecha-
nisms that link the ability of hypothalamic lipid metabolism to
the activation of KATP channels remain unknown.
RESEARCH DESIGN AND METHODS—To examine whether
hypothalamic protein kinase C (PKC) mediates the ability of
central nervous system lipids to activate KATP channels and
regulate glucose production in normal rodents, we ﬁrst activated
hypothalamic PKC in the absence or presence of KATP channel
inhibition. We then inhibited hypothalamic PKC in the presence
of lipids. Tracer-dilution methodology in combination with the
pancreatic clamp technique was used to assess the effect of
hypothalamic administrations on glucose metabolism in vivo.
RESULTS—We ﬁrst reported that direct activation of hypotha-
lamic PKC via direct hypothalamic delivery of PKC activator
1-oleoyl-2-acetyl-sn-glycerol (OAG) suppressed glucose produc-
tion. Coadministration of hypothalamic PKC- inhibitor rottlerin
with OAG prevented the ability of OAG to activate PKC- and
lower glucose production. Furthermore, hypothalamic dominant-
negative Kir6.2 expression or the delivery of the KATP channel
blocker glibenclamide abolished the glucose production-lower-
ing effects of OAG. Finally, inhibition of hypothalamic PKC
eliminated the ability of lipids to lower glucose production.
CONCLUSIONS—These studies indicate that hypothalamic
PKC activation is sufﬁcient and necessary for lowering glucose
production. Diabetes 57:2061–2065, 2008
T
he hypothalamus senses nutrients and hormones
to regulate energy and glucose homeostasis
(1–9), but the associated central nervous system
(CNS) sensing mechanisms remain unclear. A
selective increase in long-chain fatty acyl-coenzyme A
(LCFA-CoA) level in the hypothalamus leads to the acti-
vation of SUR1/Kir6.2-containing ATP-sensitive K
 (KATP)
channels and lowers glucose production (10). In contrast,
an elevation of LCFA-CoA level in the liver actually
increases glucose production during hyperinsulinemia (1).
These observations led us to hypothesize that lipid-sensing
mechanisms share similar biochemical (i.e., LCFA-CoA
accumulation) but have opposing physiological mecha-
nisms (i.e., glucose production regulation) in operation
(1).
In the peripheral tissues such as the liver and muscle, an
elevation of lipids (especially the long-chain fatty acids
[LCFAs]) activates the novel isoforms of protein kinase C
(PKC) (i.e., -,- ε , and -) to induce insulin resistance
during hyperinsulinemic-euglycemic clamps (11–16). Al-
though novel isoforms of PKC (especially - and -ε ) are
expressed in the brain (17), it is currently unknown
whether LCFAs activate hypothalamic, novel isoforms of
PKC to regulate glucose production. It has been reported
that activation of PKC leads to phosphorylation of the
conserved threonine residue (T180) in the pore-forming
subunit Kir6.2 of the KATP channels in the pancreatic
-cells (18). These channels are expressed in both -cells
and neurons (18,19), and direct activation of the hypotha-
lamic KATP channels has been shown to lower glucose
production (19). Both the PKC-induced KATP channel
activation (18) and hypothalamic KATP channels’ regula-
tion of glucose production (19) are blocked by pretreat-
ment with the KATP channel blocker glibenclamide (18,19).
It is possible that the mechanism of activation of KATP
channels in the -cells by PKC is also found in the
hypothalamus.
Based on these independent yet parallel ﬁndings, we
tested the hypothesis that activation of hypothalamic PKC
is sufﬁcient and necessary for CNS lipid-sensing mecha-
nisms to lower glucose production and regulate glucose
homeostasis (Fig. 1A).
RESEARCH DESIGN AND METHODS
We studied 8-week-old male Sprague-Dawley rats (Charles River Breeding
Laboratories). Indwelling bilateral catheters (Plastics One, Roanoke, VA)
were placed into the mediobasal hypothalamus (MBH) (3.1 mm posterior of
bregma, 0.4 mm lateral from midline, and 9.6 mm below skull surface) 2 weeks
before the experiments in vivo (20). One week later, catheters were placed in
the internal jugular vein and the carotid artery for infusion and sampling
during the clamp procedures (2). Recovery from surgery was monitored by
measuring daily food intake and body weight gain in the 3–4 days preceding
the infusion procedure. The study protocols were approved by the institu-
tional animal care and use committee of the University Health Network in
Toronto and the Albert Einstein College of Medicine in New York.
Clamp procedure. All the rats were restricted to 20 g of food the night before
the experiments to ensure the same nutritional status. Infusion studies lasted
a total of 360 min. At 0 min, MBH infusion of the various study solutions was
initiated and maintained at a rate of 0.33 l/h for 6 h. Study solutions consisted
of 250 mol/l PKC activator 1-oleoyl-2-acetyl-sn-glycerol (OAG) (dissolved in
5% DMSO), 250 mol/l OAG plus 60 mol/l bisindolylmaleimide (BIM)
(general PKC inhibitor), 250 mol/l OAG plus 60 mol/l rottlerin (Rot)
(speciﬁc PKC- inhibitor), 250 mol/l OAG plus 100 mol/l KATP channel
blocker glibenclamide (dissolved in 5% DMSO), vehicle (either saline or 5%
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DIABETES, VOL. 57, AUGUST 2008 2061DMSO), 60 mol/l BIM, 60 mol/l Rot, or 100 mol/l glibenclamide. After 2 h
of MBH infusion, a primed continuous intravenous infusion of 3-
3H-glucose
(40 Ci bolus, 0.4 Ci/min; Perkin Elmer) was begun and maintained
throughout the study to assess glucose kinetics in vivo.
In a different group of rats, intravenous saline or 20% Intralipid (mixed with
20 units/ml of heparin, 0.4 ml/h; Baxter Healthcare Corporation) infusion was
initiated at 120 min and maintained throughout the experiments. Intralipid
infused at this rate elevates plasma free fatty acid and hypothalamic LCFA-
CoA levels by 1.5- to 2.0-fold (10). Samples for determination of
3H
glucose–speciﬁc activity were obtained at 10-min intervals. For the ﬁnal2ho f
the infusion study, a pancreatic-euglycemic clamp was performed to evaluate
the effect of MBH treatments on glucose metabolism independent of changes
in glucoregulatory hormones. This involved continuous infusions of insulin
(0.8 mU  kg
1  min
1 for MBH OAG studies and 1.5 mU  kg
1  min
1 for
intravenous intralipid infusion studies) and somatostatin (3 g  kg
1  min
1)
to inhibit endogenous insulin and glucagon secretions and a variable infusion
of a 25% glucose solution that was started and periodically adjusted to
maintain the plasma glucose concentration similar to the basal levels (210–
240 min).
The data for glucose infusion rate, glucose production, and glucose uptake
were presented as an average of values obtained from the ﬁnal 30 min
(300–360 min) of the clamp studies. MBH Rot, BIM, and glibenclamide alone
did not affect glucose kinetics (data not shown). In a separate set of
experiments, we performed clamps infused with a higher dose of insulin (1.2
instead of 0.8 mU  kg
1  min
1) and administered vehicle (n  5) or OAG
(n  4) into the MBH. We found that insulin clamped at 1.2 mU  kg
1  min
1
normally suppressed glucose production from 11 to mean 	 SD 7.3 	 0.4
mg  kg
1  min
1 in MBH vehicle–treated rats. MBH OAG further suppressed
glucose production to 2.9 	 0.9 mg  kg
1  min
1 (P 
 0.01 vs. MBH vehicle)
during the clamps infused with the higher dose of insulin. The effects of MBH
OAG on glucose production suppression was additive to peripheral insulin’s
effect on the liver, although the magnitude of the drop (4.5 mg  kg
1  min
1)
was similar compared with that observed during the pancreatic basal insulin
clamps (Fig. 1C). We also performed additional pancreatic basal insulin
clamps with intracerebroventricular (icv) OAG (n  4) versus vehicle (n  5).
The data indicated that icv OAG suppressed glucose production (5.9 	 0.4 [icv
OAG, n  4] vs. 10.8 	 0.8 mg  kg
1  min
1 [icv vehicle, n  5], P 
 0.01) to
a similar extent as it was suppressed MBH OAG (Fig. 1C). At the end of all
studies, rats were anesthetized (ketamine 150 mg/kg) and tissue samples were
freeze-clamped with precooled aluminum tongs in situ. All tissue samples
were stored at 80°C for further analysis. Harvard Apparatus PHD 2000
infusion pumps were used for all infusions during the clamps.
Mediobasal hypothalamic wedge sampling. The MBH was sampled by
dissecting a wedge of tissue including the entire mediolateral and dorsoven-
tral extent of the arcuate nuclei while minimizing ventromedial nucleus tissue.
Adenovirus injection. Immediately poststereotaxic surgery, MBH cannu-
lated rats were administered 3 l of adenovirus containing dominant-negative
(DN) Kir6.2 AAA-AV (21) (3.1  10
10 plaque-forming units/ml) or green
ﬂuorescent protein (GFP) (3.0  10
10 plaque-forming units/ml) per side of
cannula, as previously described (22). Five days later, the rats underwent
vascular surgeries and clamp studies, with MBH OAG administrations per-
formed 4 days later. Preliminary studies (n  3) indicate that MBH OAG
similarly lowered glucose production in GFP-injected rats compared with
noninjected rats (n  4). Thus, the studies were combined and presented as
a single MBH OAG group in Fig. 1B and C.
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FIG. 1. Hypothalamic PKC activation lowers glucose production. A: Working hypothesis: lipids activate hypothalamic PKC to phosphorylate and
activate the hypothalamic Kir6.2/SUR1-containing KATP channels to lower glucose production. Direct MBH administration of PKC activator OAG
increased glucose infusion rate (B) and lowered glucose production (C) during the clamps. MBH OAG coinfused with general PKC inhibitor BIM
(n  5), speciﬁc PKC- inhibitor Rot (n  6), or KATP channel blocker glibenclamide (n  5) or in MBH DN Kir6.2 AAA-injected rats (n  5) failed
to increase glucose infusion rate (B) and lower glucose production (C). D: Glucose uptake was comparable in all groups. MBH vehicle (VEH) (n 
6) consisted of MBH saline (n  3) and MBH 5% DMSO (n  3). MBH OAG (n  7) consisted of MBH OAG in normal rats (n  4) and in MBH
GFP-injected rats (n  3). *P < 0.001 (ANOVA) and P < 0.01 vs. other individual groups.
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novel isoforms of PKC was assessed by comparing immunoblots of the
cytosolic- and membrane-associated fractions obtained 5 min after the MBH
DMSO, OAG, OAG  Rot, and Rot treatments in vivo. It is important to point
out that Rot has previously been shown to inhibit PKC- translocation in
neuronal cells (23). MBH wedges (8 mg) were homogenized using a
handheld glass homogenizer in lysis buffer A (20 mmol/l 3-(N-morpholino)
propanesulfonic acid [MOPS], 2 mmol/l EDTA, 0.32 mmol/l sucrose, 30 mmol/l
sodium ﬂuoride, 10 mmol/l sodium pyrophosphate, 2 mmol/l sodium or-
thovanadate, 1 mmol/l phenylmethylsulfonylﬂuoride, 3 mmol/l benzamidine, 5
mol/l pepstatin A, and 10 mol/l leupeptin). The samples were centrifuged at
500g to pellet out the nuclear fraction, and the supernatant was then
cetrifuged at 100,000g for 60 min at 4°C. The supernatant was retained as the
cytosolic fraction. The pellet fraction was washed in lysis buffer A and then
resuspended in lysis buffer B (lysis buffer A plus 1% Triton X-100). The
samples were incubated for 60 min on ice and then centrifuged at 100,000g for
60 min at 4°C. The supernatant provided the solubilized membrane fraction.
The protein concentration of all samples was determined by detergent-
compatible microbicinchoninic acid assay (microBCA, Pierce) using serum
albumin as the standard. Eight micrograms of protein in all samples were
mixed with LDS sample loading buffer and sample reducing agent (Invitrogen)
and heated to 70°C for 10 min. The mixture was then subjected to electro-
phoretic separation (4–12% bis-tris) and transferred to polyvinylidine ﬂuoride
membranes. The membranes were incubated for1hi nLi-cor blocking buffer
at room temperature and then incubated overnight at a concentration of
1:1,000 with afﬁnity-puriﬁed polyclonal antibodies speciﬁc for the various
novel isoforms of PKC (Santa Cruz). Consistent with previous ﬁndings (17), no
bands for PKC- in the MBH wedges were detected using high or low dilution
of the antibody. Membranes were washed with Tris-buffered saline plus
Tween and then incubated for1ha troom temperature with immunoreactive-
dye–conjugated IgG (Rockland). The membranes were washed again with
Tris-buffered saline-Tween and then rinsed with PBS and scanned on the
Odyssey Infrared imaging system (Li-Cor). The immunoreactive bands were
quantiﬁed using the analytical programs on the Odyssey system.
Statistical analysis. Statistical analysis was done by ANOVA to compare
across the groups followed by Tukey post hoc test to compare between
groups. Statistical analysis was accepted as signiﬁcant with a P value 
0.05.
Data are presented as means  SE.
RESULTS
To examine the glucoregulatory effects of hypothalamic
PKC activation, we infused PKC activator OAG (250
mol/l) into the MBH of conscious unrestrained rats in
vivo. The effects on glucose production and glucose up-
take induced by MBH OAG administration were assessed
by the tracer-dilution methodology and the pancreatic
basal insulin clamp technique as previously described (2).
During the clamps, MBH OAG increased exogenous glu-
cose infusion rate by 2.5-fold, compared with MBH
vehicle, which maintained euglycemia (Fig. 1B). The in-
crease in glucose infusion rate was fully accounted for by
an inhibition of glucose production (Fig. 1C) because the
rate of glucose uptake remained unchanged (Fig. 1D),
indicating that direct hypothalamic PKC activation low-
ered glucose production.
We then coinfused MBH OAG with the general PKC
inhibitor BIM (60 mol/l) or with the speciﬁc PKC-
inhibitor Rot (60 mol/l). We found that inhibition of
hypothalamic PKC, or more speciﬁcally PKC-, with both
inhibitors diminished the ability of MBH OAG to increase
exogenous infusion rate and to lower glucose production
(Fig. 1B and C). We administered OAG into the MBH in a
different group of rats at the same concentration that was
used in the clamp studies, and we found that MBH OAG
selectively induced hypothalamic PKC- plasma mem-
brane translocation (an accepted marker for PKC activa-
tion [24,25]) (Fig. 2A). Importantly, MBH OAG–induced
PKC- membrane translocation was blocked by the coad-
ministration of PKC- inhibitor Rot at the same concen-
tration that blocked the ability of MBH OAG to lower
glucose production (Fig. 1C). MBH OAG (with or without
Rot) decreased PKC-ε content in the cytosolic fraction but
with no parallel increase in the membrane fraction (Fig.
2B). Because we hypothesized that the activation of hypo-
thalamic PKC leads to the activation/phosphorylation of
the KATP channels that are located in the plasma mem-
brane, we postulate that hypothalamic PKC- but not
PKC-ε regulates glucose production. However, this remains
to be proven. Together, these data suggest that hypotha-
lamic PKC- activation lowered glucose production.
Hypothalamic KATP channels mediate CNS nutrient
sensing to regulate glucose production (1,20). Given the
ability of PKC to phosphorylate and activate the Kir6.2-
SUR1 KATP channels (18) that are expressed in both
pancreatic -cells and neurons (19), we ﬁrst tested
whether activation of hypothalamic KATP channels is re-
quired for PKC to lower glucose production with a phar-
macological approach. We coinfused MBH OAG with low
doses of the KATP channel blocker glibenclamide (100
mol/l), and this fully reversed the ability of MBH OAG to
increase glucose infusion rate and lower glucose produc-
tion (Fig. 1B and C). We next tested the role of hypotha-
lamic KATP channels with a molecular approach. DN Kir6.2
channel expression induced by an adenovirus (adenovirus-
expressing Kir6.2 AAA) disrupts the Kir6.2 channel current
by more than 90% in cardiac myocytes (21). The DN Kir6.2
AAA adenovirus expresses an AAA mutant subunit of
Kir6.2 that co-assembles with endogenous Kir6.2 and
prevents the fully assembled KATP channel complex from
conducting potassium current (21). We injected the DN
Kir6.2 AAA adenovirus or GFP previously into the MBH of
rats and performed the clamp procedure with MBH OAG
administration. MBH OAG failed to increase glucose infu-
sion rate and lower glucose production in the DN Kir6.2
AAA previously rats compared with the GFP adenovirus
rats (Fig. 1B and C). These data collectively indicate that
the hypothalamic Kir6.2/SUR1-containing KATP channel is
required for PKC to lower glucose production. Future
studies are needed to clarify whether hypothalamic PKC
directly phosphorylates/activates the KATP channels to
regulate glucose production.
During the pancreatic basal insulin clamps, an elevation
of plasma LCFA increases gluconeogenesis but not glu-
cose production because of an inhibition of glycogenolysis
(10,26,27). The activation of hypothalamic KATP channels
by an approximately twofold elevation of circulating LCFA
(induced by intravenous intralipid infusion) was recently
demonstrated to inhibit glycogenolysis and compensate
for the induction in gluconeogenesis (10). In light of the
fact that 1) LCFAs activate PKC in liver and muscle
(11–16) and 2) hypothalamic PKC-KATP channel activation
lowers glucose production (demonstrated in the current
study), we tested, using the same intravenous intralipid-
infused model (10), whether activation of hypothalamic
PKC is required for circulating LCFA to lower glucose
production. We inhibited hypothalamic PKC activation
with either MBH BIM (60 mol/l) or Rot (60 mol/l)
administration to rats that received intravenous intralipid.
MBH BIM or Rot decreased the exogenous glucose infu-
sion rate required to maintain euglycemia in rats that
received lipid infusion (Fig. 2C). The decrease in glucose
infusion rate was fully accounted for by an elevation of
glucose production, since glucose uptake was unchanged
(Fig. 2D and E). Together, these data indicate that hypo-
thalamic PKC activation is required for circulating lipids to
lower glucose production.
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DIABETES, VOL. 57, AUGUST 2008 2063Finally, we tested whether activation of hypothalamic
PKC lowers glucose production in an early-onset (3 days
of high-fat feeding) diet-induced hepatic insulin resistance
model (2,28,29). We found that during the pancreatic basal
insulin clamps, MBH OAG suppressed glucose production
in high-fat–fed rats (5.7  0.7 mg  kg
1  min
1 [MBH OAG;
n  5] vs. 11.5  0.5 mg  kg
1  min
1 [MBH vehicle; n 
5], P 
 0.001) to a similar extent as that observed in rats
given a regular diet (Fig. 1C). These data indicate that
direct PKC activation bypasses lipid-sensing defect(s) in
the hypothalamus (28) to lower glucose production in the
early onset of diet-induced insulin resistance.
DISCUSSION
Our data ﬁrst support the notion that activation of hypo-
thalamic PKC is sufﬁcient and necessary for CNS lipid-
sensing mechanisms to lower glucose production through
the activation/phosphorylation of hypothalamic Kir6.2/
SUR1-containing KATP channels. However, much work is
needed to further dissect the mechanisms in the hypothal-
amus or in other parts of this brain-liver axis that regulates
glucose production. Second, these data support the work-
ing hypothesis that lipid-sensing mechanisms in the brain
and liver share biochemical mechanisms but have oppos-
ing physiological mechanisms that regulate glucose pro-
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2064 DIABETES, VOL. 57, AUGUST 2008duction (1). Finally, our ﬁndings reveal hypothalamic PKC
as a potential therapeutic target for lowering glucose
levels in diabetes and obesity.
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